Your session is about to expire
← Back to Search
Virus Therapy
1 for Prostate Cancer (BNIT-PR-001 Trial)
Phase 1
Waitlist Available
Research Sponsored by Bavarian Nordic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group
Summary
BNIT-PR-001 is an open-label, multi-center, Phase I dosing evaluation trial of MVA-BN®-PRO in men with androgen-insensitive prostate cancer. Patients will have PSA recurrence after being treated with androgen suppression therapy or complete androgen blockade. The trial will consist of a treatment with up to 6 vaccinations with MVA-BN®-PRO at monthly intervals, followed by a 1-year follow-up phase. A vaccination may be 1, 2, or 4 injections of study vaccine. The study is designed to examine safety as well as the effect of three different doses on immune response.
Eligible Conditions
- Prostate Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Side effects data
From 2014 Phase 3 trial • 4005 Patients • NCT011446373%
Upper respiratory tract infection
1%
Oropharyngeal pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Group 4
Group 3
Group 2
Group 1
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Group I: 3Experimental Treatment1 Intervention
Highest dose level
Group II: 2Experimental Treatment1 Intervention
Middle level dose
Group III: 1Experimental Treatment1 Intervention
Lowest dose level
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Modified vaccinia ankara
FDA approved
Find a Location
Who is running the clinical trial?
Bavarian NordicLead Sponsor
62 Previous Clinical Trials
50,364 Total Patients Enrolled
1 Trials studying Prostate Cancer
120 Patients Enrolled for Prostate Cancer
Olga BandmanStudy DirectorBavarian Nordic
3 Previous Clinical Trials
165 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger